Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PLD + docetaxel versus epirubicin + docetaxel as neoadjuvant therapy for triple-negative breast cancer
ChiCTR2000040585Phase 3Completed
- Sponsor
- Southwest Health System
- Start
- Dec 2020
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in triple-negative breast cancer (TNBC) comparing PLD + docetaxel with epirubicin + docetaxel (2 arms). Primary endpoints: pathological complete response and cardiac safety evaluation. Started Dec 2020; status: completed.
02
Drugs
doxorubicinepirubicindocetaxel
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2000040585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000040585.